These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 23215687)

  • 1. Characterization of two polymorphs of lornoxicam.
    Zhang J; Tan X; Gao J; Fan W; Gao Y; Qian S
    J Pharm Pharmacol; 2013 Jan; 65(1):44-52. PubMed ID: 23215687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M; Sadeghpoor F
    Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid state manipulation of lornoxicam for cocrystals--physicochemical characterization.
    Nijhawan M; Santhosh A; Babu PR; Subrahmanyam CV
    Drug Dev Ind Pharm; 2014 Sep; 40(9):1163-72. PubMed ID: 23829186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (14) N nuclear quadrupole resonance study of piroxicam: confirmation of new polymorphic form V.
    Lavrič Z; Pirnat J; Lužnik J; Puc U; Trontelj Z; Srčič S
    J Pharm Sci; 2015 Jun; 104(6):1909-1918. PubMed ID: 25776345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
    Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
    Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal forms of piroxicam pivalate: preparation and characterization of two polymorphs.
    Giordano F; Gazzaniga A; Moyano JR; Ventura P; Zanol M; Peveri T; Carima L
    J Pharm Sci; 1998 Mar; 87(3):333-7. PubMed ID: 9523987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal forms of naproxen.
    Song JS; Sohn YT
    Arch Pharm Res; 2011 Jan; 34(1):87-90. PubMed ID: 21468919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability.
    Wu JX; Yang M; Berg Fv; Pajander J; Rades T; Rantanen J
    Eur J Pharm Sci; 2011 Dec; 44(5):610-20. PubMed ID: 22024381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and characterization of a novel polymorph of indiplon, Form α.
    Xu L; Wang J; Xiao B; Yang J; Liu Y; Huang R
    Bioorg Med Chem Lett; 2012 Jan; 22(2):963-8. PubMed ID: 22209207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermal, spectroscopic, and ab initio structural characterization of carprofen polymorphs.
    Bruni G; Gozzo F; Capsoni D; Bini M; Macchi P; Simoncic P; Berbenni V; Milanese C; Girella A; Ferrari S; Marini A
    J Pharm Sci; 2011 Jun; 100(6):2321-32. PubMed ID: 21246561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling.
    Naelapää K; Boetker JP; Veski P; Rantanen J; Rades T; Kogermann K
    Int J Pharm; 2012 Jun; 429(1-2):69-77. PubMed ID: 22433471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovation of novel sustained release compression-coated tablets for lornoxicam: formulation and in vitro investigations.
    Hamza Yel-S; Aburahma MH
    Drug Dev Ind Pharm; 2010 Mar; 36(3):337-49. PubMed ID: 19722915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piroxicam/2-hydroxypropyl-beta-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique.
    Zhang X; Wu D; Lai J; Lu Y; Yin Z; Wu W
    J Pharm Sci; 2009 Feb; 98(2):665-75. PubMed ID: 18543294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal modifications and dissolution rate of piroxicam.
    Lyn LY; Sze HW; Rajendran A; Adinarayana G; Dua K; Garg S
    Acta Pharm; 2011 Dec; 61(4):391-402. PubMed ID: 22202198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets.
    Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM
    Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
    Fini A; Cavallari C; Ospitali F
    Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
    Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
    J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of nicergoline polymorphs crystallized in several organic solvents.
    Malaj L; Censi R; Capsoni D; Pellegrino L; Bini M; Ferrari S; Gobetto R; Massarotti V; Di Martino P
    J Pharm Sci; 2011 Jul; 100(7):2610-22. PubMed ID: 21254066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.